Business Context and Reporting Period
This Form 6-K filing by UBS Group AG, dated May 13, 2024, reports on a specific corporate governance and capital structure event. The filing details the occurrence of a "Conversion Capital Availability Event" on May 10, 2024, following shareholder approval at the Annual General Meeting on April 24, 2024.
Key Financial Metrics and Capital Instruments
The filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. Instead, it focuses on the status of specific Additional Tier 1 (AT1) capital instruments. As of May 10, 2024, the following instruments became subject to equity conversion (rather than write-down) upon a trigger or viability event:
- USD 1.75 Billion in 9.250% Tier 1 Capital Notes (Issued Nov 13, 2023)
- USD 1.75 Billion in 9.250% Tier 1 Capital Notes (Issued Nov 13, 2023)
- USD 1.00 Billion in 7.750% Tier 1 Capital Notes (Issued Feb 12, 2024)
- SGD 650 Million in 5.750% Tier 1 Capital Notes (Issued Feb 21, 2024)
Material Changes
The primary material change is the shift in the loss-absorption mechanism for the listed AT1 instruments. Previously subject to a write-down mechanism, these instruments are now subject to equity conversion upon the occurrence of a trigger event or a viability event. This change was necessitated by amendments to the Articles of Association approved by shareholders.
Guidance, Risks, and Contingencies
The filing contains standard forward-looking statement disclaimers, noting that actual results may differ materially from expectations due to risks and uncertainties. It explicitly states that the instruments and any shares resulting from conversion are not registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption. The filing refers investors to the "Risk Factors" section of the most recent Form 20-F for a comprehensive discussion of risks.
Investor Verification Checklist
- Verify the specific terms of the "Conversion Capital Availability Event" in the instrument prospectuses.
- Confirm the current regulatory status of the AT1 instruments regarding the shift from write-down to equity conversion.
- Review the most recent Form 20-F for detailed risk factors and capital adequacy ratios.
- Check for any subsequent filings regarding the actual conversion or write-down of these instruments if a trigger event occurs.